Media Partners

EBR informs and educates on the latest developments and innovations in drug discovery in the pharma sector. Focusing on research and development in pharma, EBR features discussions on cutting-edge science, including topics such as oncology, cell and gene therapies, biologics and degenerative diseases, allowing contributors to highlight their own most exciting research and analysis, and their potential impacts.

To get in touch, please email either Louise (Media Manager) louise@samedanltd.com or Charlie (Editor) charlie@samedanltd.com.

IOS Press is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation).  Specifically, publish Human Antibodies an international journal designed to bring together all aspects of human hybridomas and antibody technology, along with factors that modulate host antibody repertoire and effectiveness, such as vaccines, infectious agents, and microbiome." In addition, we offer specialized services that support scientific advancement.

Bioanalysis Zone provides bioanalysts with a range of resources, including: the latest bioanalytical news; articles from Bioanalysis; exclusive interviews and commentaries; informative webinars; Spotlights focusing on bioanalytical ‘hot topics’; a business directory; and annual awards to show recognition of outstanding achievements in the field. Our mission is to advance the field of bioanalysis by increasing subject understanding and sharing of knowledge across barriers to unite the bioanalytical community.

Antibodies is an international, peer-reviewed open access journal that provides an advanced forum for scientific publications related to antibodies and antigens.

• High Visibility: Covered by Scopus (Citescore 9.6), ESCI (Web of Science, IF 4.7), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases;
• Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 4.9 days (median values for papers published in this journal in the second half of 2023).
• Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

ADC Review, Journal of Antibody-drug Conjugates launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.

At SelectScience® we are accelerating science by connecting scientific communities with trusted solutions. We produce and publish high-quality digital content and deliver content marketing solutions, whilst also informing scientists about the best products and technologies in their field through the power of peer-to-peer recommendation and reviews.